Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort

J Rheumatol. 2020 Mar;47(3):449-460. doi: 10.3899/jrheum.190522. Epub 2019 Aug 15.

Abstract

Objective: To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout.

Methods: We used US Veterans Affairs (VA) databases from 2002-2012. Eligible patients had ≥ 1 inpatient or ≥ 2 outpatient visits with a diagnostic code for gout, filled a new index allopurinol prescription, had at least 1 posttreatment SU level measured, and met the 12-month observability rule. Treatment successes were defined as the achievement of postindex SU < 6 mg/dl (success 1) and postindex SU < 6 mg/dl that was sustained (success 2).

Results: Of the 198,839 unique patients with allopurinol use, 41,153 unique patients (with 47,072 episodes) and 17,402 unique patients (with 18,323 episodes) were eligible for analyses for success 1 and success 2; 42% each achieved (success 1) or achieved and maintained postindex SU < 6 mg/dl (success 2). In multivariable-adjusted models, factors associated with significantly higher odds of both outcomes were older age, normal body mass index, Deyo-Charlson index score of 0, rheumatologist as the main provider rather than non-rheumatologist, midwestern US location for the healthcare facility, a lower hospital bed size, military service connection for medical conditions of 50% or more (a measure of healthcare access priority), longer distance to the nearest VA facility, and lower preindex SU.

Conclusion: We identified novel factors associated with maintaining SU < 6 mg/dl based on a theoretical model. Several potentially modifiable factors can be targeted by individual/provider/systems interventions for improving successful achievement and maintenance of target SU in patients with gout.

Keywords: ALLOPURINOL; EFFECTIVENESS; GOUT; PREDICTORS; TARGET SERUM URATE.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Allopurinol / therapeutic use*
  • Comorbidity
  • Female
  • Follow-Up Studies
  • Gout / blood*
  • Gout / drug therapy*
  • Gout / epidemiology
  • Gout Suppressants / therapeutic use*
  • Health Services Accessibility
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Severity of Illness Index
  • Treatment Outcome
  • United States / epidemiology
  • Uric Acid / blood*
  • Veterans*

Substances

  • Gout Suppressants
  • Uric Acid
  • Allopurinol